MNL Pharma

MNL Pharma was a Welsh biotechnology company focused on the discovery and development of carbohydrate-based therapeutics, specifically iminosugars derived from natural sources. The company's research centered on modulating glycosidase and glycosyltransferase enzymes, which play critical roles in protein folding and cell signaling. Its lead clinical candidate, MNL168, was an orally available immunomodulator that reached Phase 1 clinical trials for patients with advanced solid tumors. MNL Pharma's technology platform was built on identifying bioactive compounds from plant and microbial sources, often in collaboration with academic institutions like the University of Oxford. Despite its innovative approach to glycobiology and backing from Merlin Biosciences, the company faced financial challenges and entered administration in 2004.